Trials / Completed
CompletedNCT04965636
Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mepolizumab | Mepolizumab will be provided in pre-filled safety syringe |
Timeline
- Start date
- 2022-07-11
- Primary completion
- 2025-10-28
- Completion
- 2025-10-28
- First posted
- 2021-07-16
- Last updated
- 2025-12-04
Locations
14 sites across 6 countries: United States, Argentina, Brazil, Israel, Netherlands, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04965636. Inclusion in this directory is not an endorsement.